Low molecular weight heparin is derived from an unfractionated
heparin with an average molecular weight of less than 8,000 Da. Low
molecular weight heparins are extracted by enzymatic or chemical
depolymerization of unfractionated heparin. Low molecular weight
heparins have fewer side effects as compared to unfractionated
heparins, which involve lesser risk of heparin-induced osteopenia and
heparin-induced thrombocytopenia (HIT). Currently, low molecular
weight heparin forms the standard of care drugs and is widely used
for the treatment and prophylaxis of arterial and venous thrombosis.
Dose consideration for low molecular weight heparin depends on a
patient’s weight. In 2014, researchers at the Rensselaer
Polytechnic Institute and the University of North Carolina (UNC)
developed a synthetic form of low molecular weight heparin that is
safe and can be reversed in activity using an antidote called
protamine. According to the research, this synthetic heparin is safer
and cheaper than the available heparin which is derived from
animals.
Report Overview @
https://www.transparencymarketresearch.com/low-molecular-weight-heparin-market.html
Proven benefits of low molecular weight heparin over unfractionated
heparin are driving the demand for low molecular weight heparin
globally, which in turn is fuelling the growth of the market. The
demand for low molecular weight heparin is expected to grow
exponentially in the next few years due to increasing usage in
surgeries and in the treatment of coagulation disorders. However,
lack of its ability to reverse the effect of overdose resulting in
the development of HIT and other bleeding disorders restrains the
growth of the global low molecular weight heparin market.
The global low molecular weight heparin market is segmented on the
basis of type of molecule, type of packaging, dosing by body weight,
approved indication, end-user, and region. In terms of type of
molecule, the market is segmented into Lovenox (enoxaparin), Fragmin
(Dalteparin), Innohep (tinzaparin), and others. Based on the type of
packaging, the market is classified into multi-dose vial, single-dose
vial, prefilled or preloaded syringe, unit dose syringe, and ampoule.
On the basis of dosing by body weight, the market is categorized into
31 to 40 Kg, 41 to 50 Kg, 51 to 60 Kg, 61 to 70 Kg, 71 to 80 Kg, 81
to 90 Kg, and above 91 Kg.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32201
In terms of approved indication, the market is divided into
prophylaxis in hip replacement surgery, prophylaxis in knee
replacement surgery, prophylaxis in abdominal surgery, prophylaxis in
acutely ill medical patients, secondary prophylaxis or extended
treatment in cancer patients, inpatient treatment of deep vein
thrombosis without pulmonary embolism, outpatient treatment of deep
vein thrombosis with or without pulmonary embolism, unstable angina
and non-ST elevated MI, and acute ST-elevation MI. In terms of
end-user, the market is segmented into hospitals, nursing homes &
private clinics, assisted living facilities & long-term care
institutions, and home health care.
Geographically, the global low molecular weight heparin market is
distributed over North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. Europe and North America hold a large
market share owing to rise in the geriatric population that has an
impact on the prevalence of venous thrombosis. The European
Commission (Eurostat) stated that the geriatric population in Europe
is estimated to reach 525 million by 2035. The Asia Pacific and
Middle East & Africa markets are anticipated to grow during the
forecast period due to increasing birth rate. The National Institute
for Health and Care Excellence (NICE) and the Royal College of
Obstetricians and Gynaecologists (RCOG) recommend low molecular
weight heparin as the most appropriate heparin to be used during
pregnancy due to its inability to cross the placenta.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=32201<ype=S
Key players operating in the global low molecular weight heparin
market include Sanofi S.A., Pfizer, Inc., LEO Pharma A/S, and
Novartis AG.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment